For 15 straight years, Medicare Advantage grew without interruption. More enrollees signed up, more insurers entered the market, and more plans advertised $0 monthly premiums bundled with dental, vision, and hearing benefits that traditional Medicare does not cover. That unbroken streak is now over.
The Centers for Medicare and Medicaid Services announced that the average monthly premium for Medicare Advantage will fall to $14.00 in 2026, down from $16.40 in 2025, a roughly 15 percent decline. But the lower price tag comes alongside a development the program has not seen in more than a decade: CMS projects total enrollment of about 34 million, a figure the agency described as “stable” but one that, after accounting for mid-year attrition and plan exits, represents the first time growth has stalled or reversed since Medicare Advantage began its modern expansion.
The combination matters to the roughly 33.8 million people currently enrolled in a private Medicare plan. Cheaper premiums sound like good news. A program that has stopped growing raises harder questions about what beneficiaries are actually getting for their money.
How Medicare Advantage grew from niche option to majority choice
Medicare Advantage covered about 11 million people in 2010, according to the Kaiser Family Foundation (KFF). By 2024, enrollment had tripled past 33 million, meaning more than half of all Medicare beneficiaries had chosen a private plan over traditional fee-for-service Medicare. That growth was driven by zero-dollar premium offerings, supplemental benefits unavailable under traditional Medicare, and aggressive insurer marketing during annual enrollment periods.
The federal government fueled the expansion by paying insurers a per-beneficiary rate that, in many counties, exceeded what traditional Medicare would have spent on the same person. The Medicare Payment Advisory Commission (MedPAC) flagged this gap repeatedly in its annual reports to Congress, estimating that Medicare Advantage cost taxpayers more per enrollee than traditional Medicare in a majority of markets.
That dynamic made the program enormously profitable for large insurers. It also made it vulnerable to any policy shift that tightened the flow of federal dollars.
What is driving premiums down
The $14.00 average premium is a national figure spanning HMOs, PPOs, Special Needs Plans, and every other Medicare Advantage plan type. It reflects insurer bids submitted to CMS for the 2026 contract year. Insurers set their own premiums based on projected medical costs, expected enrollment, and the federal benchmark payments they receive for each member. CMS does not dictate premiums, but its payment rates shape what insurers can afford to offer.
Several policy changes are squeezing insurer margins and pushing premiums lower as companies compete to hold onto members:
- Risk-adjustment model overhaul (V28): CMS has been phasing in updates to the formula it uses to calculate payments based on enrollee health status. The new model reduces payments for certain diagnostic codes that insurers had used to boost revenue, effectively cutting per-member income for many plans.
- Star Ratings methodology changes: CMS revised how it calculates the quality Star Ratings that determine whether plans receive bonus payments. Several large insurers saw their ratings drop, which reduced the bonus dollars available to fund richer benefits or absorb premium costs.
- Competitive pressure: With growth slowing, insurers are pricing aggressively to retain existing members rather than counting on a rising tide of new enrollees to fill their rolls.
The result is a lower sticker price on many plans. But that number alone does not tell beneficiaries what they will actually pay.
Why a lower premium does not always mean lower costs
A plan that cuts its monthly premium from $25 to $0 can recoup that revenue by raising copayments for specialist visits, increasing the annual out-of-pocket maximum, narrowing its provider network, or tightening prior-authorization requirements for procedures and medications. A beneficiary who picks a plan based solely on the premium could end up paying hundreds or thousands more over the course of a year.
Consider a hypothetical enrollee in South Florida, one of the most competitive Medicare Advantage markets in the country. She might find dozens of $0-premium plans available in her ZIP code. But if her cardiologist is no longer in network, or her biologic medication now requires prior authorization and a step-therapy protocol, the “free” plan could cost her far more in time, frustration, and out-of-pocket spending than a $30-a-month plan that preserves her current access.
Anyone enrolled in Medicare Advantage, or considering it, should review their plan’s 2026 Annual Notice of Change and Evidence of Coverage documents. The Medicare Plan Finder tool allows side-by-side comparisons of premiums, deductibles, drug formularies, and provider networks.
Where the enrollment plateau is showing up
The enrollment shift is not uniform. UnitedHealthcare, Humana, and CVS Health’s Aetna unit together account for a majority of all Medicare Advantage members nationwide. Each faces a different mix of pressures from updated CMS benchmarks, state-level market conditions, and benefit design choices that determine whether members stay, switch, or leave for traditional Medicare.
Humana, the second-largest MA insurer, disclosed in early 2025 that it expected to lose members after exiting certain counties where updated payment rates made its plans unprofitable. Other regional insurers made similar decisions, pulling out of rural markets where provider networks were already thin and per-member costs were high.
CMS has not yet published a 2026 contract-level breakdown showing which carriers gained or lost enrollees, so the full competitive picture remains incomplete as of late May 2026. The agency’s enrollment data hub posts monthly files that allow independent researchers to track actual sign-ups against projections as the year progresses.
The Part D factor
One underappreciated force reshaping Medicare Advantage enrollment is the Inflation Reduction Act’s $2,000 annual cap on out-of-pocket prescription drug spending under Part D, which took effect in 2025. Before the cap, many beneficiaries chose Medicare Advantage partly because its bundled drug coverage offered more predictable costs than standalone Part D plans paired with traditional Medicare.
With the $2,000 cap now applying to all Part D plans, including standalone options, that advantage has narrowed. A beneficiary who previously needed Medicare Advantage to manage drug costs may now find that traditional Medicare plus a standalone Part D plan and a Medigap supplemental policy offers comparable or better coverage, especially if they want unrestricted access to any doctor who accepts Medicare.
What comes next for the program
Whether the 2026 enrollment plateau becomes a lasting trend or a one-year pause depends on decisions that are still unfolding. If the dip is concentrated in markets where insurers pulled out, enrollment could rebound once new competitors enter those areas. If beneficiaries are actively choosing to return to traditional Medicare because of frustration with narrow networks or prior-authorization barriers, the shift could deepen.
MedPAC has recommended that Congress reduce the benchmarks used to pay Medicare Advantage plans, bringing per-beneficiary spending closer to what traditional Medicare costs. If lawmakers act on that recommendation, insurers would face further pressure to cut benefits, raise premiums, or exit markets, any of which could accelerate enrollment declines.
On the other hand, Medicare Advantage still offers benefits that traditional Medicare does not: annual out-of-pocket maximums, bundled dental and vision coverage, and care-coordination programs that many enrollees value. Those features give the program a structural floor of demand that is unlikely to collapse overnight.
For now, the most honest reading of the data is simple. After more than a decade of uninterrupted growth, Medicare Advantage has hit a plateau. Premiums are lower on paper, but the benefits behind those premiums are shifting in ways that every enrollee should examine closely. The monthly enrollment files CMS publishes throughout the year will show whether the program’s expansion era has simply paused or begun to reverse.
David M. Keller is a finance writer based in Columbus, Ohio, covering personal finance and consumer-focused economic topics. He earned his degree in journalism from Ohio University and began his career reporting on local business and economic trends for a regional media outlet. Since then, he has contributed to a variety of online publications, focusing on clear, practical coverage of topics such as cost of living, debt, and everyday financial decision-making.
